Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Four ...

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year. AnaptysBio (ANAB) has seen solid earnings estimate revision ...

As January comes to an end, my InvestorPlace colleague Luke Lango is gearing up his February Auspex portfolio. Luke’s powerful Auspex stock screener is built to help find the strongest stocks at the ...

The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with cobolimab, which is being tested alongside GSK’s PD-1 ...